Ascione E, De Lucia A, Imperiali M, Varricchio A, Motta G
ENT Institute, Second University of Naples, Naples, Italy.
Chem Immunol Allergy. 2003;82:89-98. doi: 10.1159/000071543.
In patients with allergic rhinitis local nasal immunotherapy (LNIT) appears to offer considerable advantages over other hyposensitization methods. The aim of our study was to obtain further confirmation of the validity of LNIT.
A randomized, double-blind, placebo-controlled study of LNIT in patients allergic to Parietaria and Dermathophagoides was performed. Patients were evaluated, before and after treatment, with symptom and medication scores, specific nasal provocation tests, anterior rhinomanometry and mucociliary clearance time.
Compared to placebo the clinical efficacy of LNIT was confirmed by a reduction of clinical symptoms and drug intake. In the active group the reduction of allergen-specific nasal reactivity was significant. No local or systemic side effects were observed.
The clinical efficacy of LNIT suggests that this therapy is effective in the prophylaxis of allergic rhinitis. Finally, there is no conflict between LNIT and drug treatment.
在变应性鼻炎患者中，局部鼻免疫疗法（LNIT）似乎比其他减敏方法具有相当大的优势。我们研究的目的是进一步证实LNIT的有效性。
对豚草和尘螨过敏的患者进行了一项LNIT的随机、双盲、安慰剂对照研究。在治疗前后，通过症状和药物评分、特异性鼻激发试验、前鼻测压和黏液纤毛清除时间对患者进行评估。
与安慰剂相比，LNIT的临床疗效通过临床症状的减轻和药物摄入量的减少得到证实。在活性组中，变应原特异性鼻反应性的降低是显著的。未观察到局部或全身副作用。
LNIT的临床疗效表明该疗法在预防变应性鼻炎方面是有效的。最后，LNIT与药物治疗之间不存在冲突。
